Complete financial analysis of Synlogic, Inc. (SYBX) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Synlogic, Inc., a leading company in the Biotechnology industry within the Healthcare sector.
You may be interested
- Artisan Acquisition Corp. (ARTAU) Income Statement Analysis – Financial Results
- Fission Uranium Corp. (FCU.TO) Income Statement Analysis – Financial Results
- Reynaldo’s Mexican Food Company, LLC (RYNL) Income Statement Analysis – Financial Results
- Railcare Group AB (publ) (RAIL.ST) Income Statement Analysis – Financial Results
- Faraday Copper Corp. (CPPKF) Income Statement Analysis – Financial Results
Synlogic, Inc. (SYBX)
About Synlogic, Inc.
Synlogic, Inc., a clinical-stage biopharmaceutical company, engages in the discovery and development of synthetic biotic medicines to treat metabolic and immunological diseases in the United States. Its therapeutic programs include SYNB1618 and SYNB1934 that are orally administered, non-systemically absorbed drug candidates, which are in Phase II clinical trials to treat phenylketonuria; SYNB1353, an orally administered, non-systemically absorbed drug candidate to treat homocystinuria; and SYNB8802, an orally administered, non-systemically absorbed drug candidate that is in Phase I clinical trial for the treatment of enteric hyperoxaluria. The company is also developing SYNB1891, an intratumorally administered synthetic biotic medicine that is in Phase I clinical trial to treat solid tumors and lymphoma. It has a collaboration agreement with F. Hoffmann-La Roche Ltd; Hoffmann-La Roche Inc.; and Ginkgo Bioworks, Inc. Synlogic, Inc. is headquartered in Cambridge, Massachusetts.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 3.37M | 1.18M | 1.75M | 545.00K | 2.22M | 2.52M | 2.44M | 444.00K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Cost of Revenue | 0.00 | 5.67M | 0.00 | 0.00 | 0.00 | 14.90M | 0.00 | 159.00K | 54.00K | 0.00 | 0.00 | 0.00 | 37.00K |
| Gross Profit | 3.37M | -4.49M | 1.75M | 545.00K | 2.22M | -12.38M | 2.44M | 285.00K | -54.00K | 0.00 | 0.00 | 0.00 | -37.00K |
| Gross Profit Ratio | 100.00% | -380.42% | 100.00% | 100.00% | 100.00% | -491.15% | 100.00% | 64.19% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Research & Development | 43.97M | 52.04M | 47.13M | 47.47M | 41.91M | 38.03M | 30.34M | 13.93M | 18.95M | 10.55M | 4.39M | 2.74M | 980.00K |
| General & Administrative | 14.56M | 16.56M | 15.39M | 13.54M | 14.73M | 15.72M | 12.93M | 8.12M | 6.08M | 3.37M | 2.38M | 1.56M | 0.00 |
| Selling & Marketing | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 14.56M | 16.56M | 15.39M | 13.54M | 14.73M | 15.72M | 12.93M | 8.12M | 6.08M | 3.37M | 2.38M | 1.56M | 1.47M |
| Other Expenses | 0.00 | 7.00K | 204.00K | 1.29M | 3.04M | 2.80M | 447.00K | 4.57M | 0.00 | 0.00 | 339.00K | 0.00 | 0.00 |
| Operating Expenses | 58.53M | 68.60M | 62.52M | 61.01M | 56.63M | 53.75M | 43.27M | 22.05M | 25.03M | 13.91M | 6.78M | 4.30M | 2.45M |
| Cost & Expenses | 58.53M | 68.60M | 62.52M | 61.01M | 56.63M | 53.75M | 43.27M | 22.05M | 25.03M | 13.91M | 6.78M | 4.30M | 2.48M |
| Interest Income | 2.47M | 1.27M | 210.00K | 1.30M | 3.06M | 2.84M | 504.00K | 350.00K | 44.00K | 0.00 | 0.00 | 0.00 | 0.00 |
| Interest Expense | 1.00K | 2.00K | 2.00K | 6.00K | 21.00K | 43.00K | 57.00K | 0.00 | 44.00K | 0.00 | 0.00 | 355.00K | 399.00K |
| Depreciation & Amortization | 1.96M | 3.79M | 2.44M | 2.64M | 2.70M | 2.42M | 2.31M | 692.00K | 54.00K | 35.00K | 36.00K | 37.00K | 37.00K |
| EBITDA | -53.20M | -63.63M | -58.12M | -57.83M | -47.28M | -45.97M | -38.01M | -24.70M | -24.93M | -15.80M | -6.74M | -3.27M | -2.45M |
| EBITDA Ratio | -1,578.26% | -5,391.95% | -3,464.37% | -11,094.68% | -2,446.45% | -2,032.94% | -1,670.38% | -3,936.49% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Operating Income | -55.16M | -67.42M | -60.77M | -60.47M | -54.41M | -51.23M | -40.82M | -26.62M | -25.03M | -15.83M | -6.78M | -4.30M | -2.48M |
| Operating Income Ratio | -1,636.34% | -5,713.47% | -3,464.37% | -11,094.68% | -2,446.45% | -2,032.94% | -1,670.38% | -5,995.05% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Total Other Income/Expenses | -2.11M | 1.27M | 204.00K | 1.29M | 3.04M | 2.80M | 447.00K | 10.00K | 44.00K | -1.92M | 339.00K | 646.00K | -399.00K |
| Income Before Tax | -57.27M | -66.15M | -60.56M | -59.17M | -51.37M | -48.44M | -40.38M | -26.27M | -24.98M | -15.83M | -6.44M | -3.66M | -2.88M |
| Income Before Tax Ratio | -1,698.84% | -5,605.68% | -3,452.74% | -10,857.43% | -2,309.94% | -1,922.02% | -1,652.09% | -5,916.22% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Income Tax Expense | 14.00K | -1.27M | -2.44M | -2.64M | -2.70M | 2.84M | -2.31M | 4.06M | -54.00K | 0.00 | 0.00 | 355.00K | 0.00 |
| Net Income | -57.28M | -64.88M | -58.12M | -56.54M | -48.67M | -48.44M | -40.38M | -26.27M | -24.98M | -15.83M | -6.44M | -3.66M | -2.88M |
| Net Income Ratio | -1,699.26% | -5,497.88% | -3,313.45% | -10,373.76% | -2,188.44% | -1,922.02% | -1,652.09% | -5,916.22% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| EPS | -8.81 | -13.57 | -15.76 | -23.67 | -24.11 | -30.42 | -90.07 | -8.83 | -34.90 | -13.98 | -5.68 | -4.52 | -20.96 |
| EPS Diluted | -8.81 | -13.57 | -15.76 | -23.67 | -24.11 | -30.42 | -90.07 | -8.83 | -34.90 | -13.98 | -5.68 | -4.52 | -20.96 |
| Weighted Avg Shares Out | 6.50M | 4.78M | 3.69M | 2.39M | 2.02M | 1.59M | 448.31K | 2.98M | 715.76K | 1.13M | 1.13M | 809.17K | 198.39K |
| Weighted Avg Shares Out (Dil) | 6.50M | 4.78M | 3.69M | 2.39M | 2.02M | 1.59M | 448.31K | 2.98M | 715.76K | 1.13M | 1.13M | 809.17K | 198.39K |
Synlogic Reports Third Quarter 2020 Financial Results and Provides Business Update
CAMBRIDGE, Mass., Nov. 5, 2020 /PRNewswire/ -- Synlogic, Inc. (Nasdaq: SYBX), a clinical stage company bringing the transformative potential of synthetic biology to medicine, today reported financial results for the third quarter ended Sept. 30, 2020, and provided an update...
Synlogic Announces Third Quarter 2019 Conference Call and Webcast
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Synlogic, Inc. (Nasdaq: SYBX), a clinical stage company applying synthetic biology to beneficial microbes to develop novel, living medicines, announced today that the Company will release its third quarter 2019 financial results after the market closes on Tuesday,...
Synlogic Announces Second Quarter 2019 Conference Call and Webcast
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Synlogic, Inc. (Nasdaq: SYBX), a clinical stage company applying synthetic biology to beneficial microbes to develop novel, living medicines, announced today that the Company will release its second quarter 2019 financial results after the market closes on Thursday,...
Synlogic Reports Positive Top-line Data from Phase 1/2a Study of SYNB1618 in Patients with Phenylketonuria and Guides to Next Phase of Development
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Synlogic, Inc., (Nasdaq: SYBX), a clinical stage company developing a novel class of Synthetic BioticTM therapeutics, today announced positive top-line clinical data from patient cohorts of a randomized, double-blind, placebo-controlled Phase 1/2a study of SYNB1618, which is being...
Synlogic and Ginkgo Bioworks Establish Transformational Platform Collaboration for the Accelerated Development of Novel Synthetic Biotic™ Medicines
CAMBRIDGE, Mass. & BOSTON--(BUSINESS WIRE)--Synlogic, Inc. (Nasdaq: SYBX), a clinical-stage company applying synthetic biology to beneficial microbes to develop novel, living medicines and Ginkgo Bioworks, the organism company, today announced a platform collaboration to accelerate expansion and development of Synlogic’s...
Synlogic Announces First Quarter 2019 Conference Call and Webcast
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Synlogic, Inc. (Nasdaq: SYBX), a clinical stage company applying synthetic biology to beneficial microbes to develop novel, living medicines, announced today that the Company will release its first quarter 2019 financial results after the market closes on Thursday,...
Synlogic Announces Fourth Quarter and Full Year 2018 Conference Call and Webcast
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Synlogic, Inc. (Nasdaq: SYBX), a clinical stage company applying synthetic biology to probiotics to develop novel, living medicines, announced today that the Company will release its fourth quarter and full year 2018 financial results before the market opens...
Synlogic Announces Third Quarter 2018 Conference Call and Webcast
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Synlogic, Inc. (Nasdaq: SYBX), announced today that the Company will release its third quarter 2018 financial results after the market closes on Tuesday, November 13, 2018. The press release will be followed by a conference call at 5:00...
Synlogic Reports Positive Interim Phase 1/2a Data Demonstrating Safety, Tolerability and Proof-of-Mechanism in Healthy Volunteers for SYNB1618, in Development for the Management of Phenylketonuria (PKU)
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Synlogic, Inc., (Nasdaq:SYBX) a clinical stage company applying synthetic biology to probiotics to develop novel, living medicines, today announced positive interim clinical data from the healthy volunteer (HV) arm of its ongoing Phase 1/2a study of SYNB1618 in...
Source: https://incomestatements.info
Category: Stock Reports